Rebate Proposals Targeting Single-Use Vials May Be Barking Up The Wrong Tree
Policymakers should instead focus on increasing efficiencies in drug development, distribution and reimbursement, National Academies report says, while also seeking broad policies like HHS direct negotiation for drug prices in Medicare.
You may also be interested in...
The upcoming implementation of a new ‘refund’ program for unused drugs included in single-use vials is a remarkable story of a policy idea moving from academic research into the real world. But the actual impact sure has shrunk along the way.
Manufacturers who sell single-use vials for products covered by Part B have about 16 months to consider pricing or packaging changes that may minimize exposure to a new refund for ‘wasted’ drug.
Senate negotiators opt to delay but not withdraw the pharma-backed rebate rule and target a relatively small reform aimed at allowing Medicare Part B to recoup the cost of leftover physician-administered drugs